Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint

Jacek Kubica¹, Piotr Adamski¹, Przemysław Paciorek¹, ², Jerzy R. Ładny⁴, Zbigniew Kalarus⁵, Waldemar Banasiak⁶, Waclaw Kochman⁶, Jaroslaw Goracy⁷, Beata Wożakowska-Kapłon⁸, Eliano Pio Navarese¹, Andrzej Kleinrok⁹, Robert Gil¹⁰, Maciej Lesiak¹¹, Jaroslaw Droźd¹², Aldona Kubica¹, Krzysztof J. Filipiak¹³, Jarosław Kaźmierczak⁷, Aleksander Goch¹, Stefan Grajek¹¹, Andrzej Basiński⁶, Łukasz Szarpak¹³, Grzegorz Grześk¹, Piotr Hoffman¹⁴, Wojciech Wojakowski¹⁵, Zbigniew Gąsior¹⁶, Sławomir Dobrzycki¹⁶, Jolanta M. Siller-Matula¹⁷, Adam Witkowski¹⁴, Wiktor Kuliczkowski¹⁸, Marcin Gruchała⁶, Dariusz Timler¹², Grzegorz Opolski¹³, Dariusz Dudek¹⁹, Jacek Legutko¹⁹, Marzenna Zieleńska¹², Jarosław Wójcik²⁰

¹Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; ²Regional Emergency Ambulance Service, Bydgoszcz, Poland; ³Medical University, Białystok, Poland; ⁴Medical University of Silesia, Zabrze, Poland; ⁵ª Military Hospital, Wroclaw, Poland; ⁶Medical University of Gdansk, Poland; ⁷Pomeranian Medical University, Szczecin, Poland; ⁸Jan Kochanowski University, Kielce, Poland; ⁹Regional Hospital, Zamosc, Poland; ¹⁰Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland; ¹¹Poznan University of Medical Science, Poznan, Poland; ¹²Medical University of Lodz, Poland; ¹³Medical University of Warsaw, Poland; ¹⁴Cardinal Stefan Wyszyński Institute of Cardiology, Warsaw, Poland; ¹⁵School of Medicine, Medical University of Silesia, Katowice, Poland; ¹⁶SHS Medical University of Silesia, Katowice, Poland; ¹⁷Medical University of Vienna, Austria; ¹⁸Wroclaw Medical University, Wroclaw, Poland; ¹⁹Cardiologium Medicum, Jagiellonian University, Krakow, Poland; ²⁰Medical University of Lublin, Poland

Abstract
A group of Polish experts in cardiology and emergency medicine, encouraged by the European Society of Cardiology (ESC) guidelines, have recently published common recommendations for medical emergency teams regarding the pre-hospital management of patients with acute coronary syndrome. Due to the recent publication of the 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation and 2017 focused update on dual antiplatelet therapy in coronary artery disease the current panel of experts decided to update the previous standpoint. Moreover, new data coming from studies presented after the previous document was issued were also taken into consideration. (Cardiol J 2018; 25, 3: 291–300)

Key words: acute coronary syndrome, clopidogrel, emergency team, myocardial infarction, prasugrel, ticagrelor
Introduction

A group of Polish experts in cardiology and emergency medicine, encouraged by the European Society of Cardiology (ESC) guidelines, have recently published common recommendations for medical emergency teams regarding the pre-hospital management of patients with acute coronary syndrome (ACS). These recommendations are also meant for the organization of regional networks designed to provide reperfusion therapy expeditiously and effectively [1]. Due to the recent publication of the 2017 ESC guidelines for the management of acute myocardial infarction (MI) in patients presenting with ST-segment elevation and the 2017 update focused on dual antiplatelet therapy (DAPT) in coronary artery disease, the current panel of experts decided to update the previous standpoint [1–3]. Moreover, new data coming from studies presented after the previous document was issued, were also taken into consideration.

In spite of the improvement in prognosis for patients with ACS, particularly with MI, which has been observed in recent years, this form of coronary artery disease is still associated with high risk of death. The total in-hospital mortality rate among patients with MI in Poland is about 11% (6% for patients managed invasively vs. 18–24% for patients receiving conservative treatment), while the mortality rate in the first 12 months after MI is up to 19% [4]. It should be noted that, despite a major reduction in the in-hospital mortality rate, pre-hospital mortality remains relatively high.

Due to different management strategies applied in patients with ACS, the diagnosis is commonly classified as ST-segment elevation MI (STEMI) or non-ST-segment elevation ACS (NSTE-ACS), which includes non-ST-segment elevation MI (NSTEMI) and unstable angina (UA) [1].

Diagnosis and logistics of ACS patients

According to the current guidelines, the ambulance system plays a critical role in the early management of ACS patients and is not only a mode of transportation, but also a system to enhance early diagnosis, triage, and treatment [5, 6]. To improve quality of care and decrease adequate treatment delay, an early working diagnosis of ACS and risk stratification should be conducted as soon as possible. Presence of concordant ST-segment elevation (i.e. in leads with positive QRS deflections) appears to be one of the best indicators of ongoing MI with an occluded infarct artery [7]. In patients with a clinical suspicion of STEMI, reperfusion therapy needs to be initiated as soon as possible, thus direct transportation to centres with invasive cardiology facilities is indispensable [8]. Subjects with ongoing myocardial ischemia and left or right bundle branch block should be managed similar to STEMI patients, regardless of whether the bundle branch block has been previously known [2, 9]. Other atypical electrocardiographic presentations that should prompt a primary percutaneous coronary intervention (PCI) strategy in patients with ongoing symptoms consistent with myocardial ischemia are: ventricular paced rhythm (during right ventricular pacing, the electrocardiogram [ECG] shows left bundle branch block), isolated posterior MI (isolated ST depression ≥ 0.5 mm in leads V1–V3 and ST-segment elevation (≥ 0.5 mm) in posterior chest wall leads V7–V9), ischemia due to left main coronary artery occlusion or multivessel disease (ST depression ≥ 1 mm in eight or more surface leads, coupled with ST-segment elevation in aVR and/or V1) [2].

In the absence of ST-segment elevation or atypical electrocardiographic presentations mentioned above, an immediate PCI strategy is indicated in patients with suspected ongoing ischemic symptoms suggestive of MI and at least one of the following criteria present (NSTE-ACS of very high risk) [10]:

— hemodynamic instability or cardiogenic shock;
— recurrent or ongoing chest pain refractory to medical treatment;
— life-threatening arrhythmias or cardiac arrest;
— mechanical complications of MI;
— acute heart failure;
— recurrent dynamic ST-segment or T-wave changes, particularly with intermittent ST-segment elevation.

The ECG monitoring should be applied immediately in all patients with initial diagnosis of ACS in order to detect life-threatening arrhythmias and allow prompt defibrillation, if indicated [2]. A strategy aimed to reduce treatment delay leading to mortality reduction in STEMI and very high risk NSTE-ACS patients should be applied. Therefore teleconsultation including transmission of patients’ 12-lead ECG and clinical data to the destination centre should be performed within 10 min from the first medical contact [1, 2, 11]. This allows immediate activation of the interventional team and direct transportation of patients triaged for a primary PCI strategy to the catheterization laboratory, bypassing the emergency department [1, 2, 11–16].
The efficient treatment of ACS patients requires appropriate ambulance equipment and staff competences. All medical emergency system ambulances should be equipped with ECG recorders, defibrillators, and at least one person trained in advanced life support. All ambulance personnel should be trained to recognize clinical symptoms of acute MI, record and transmit ECG, administer oxygen when appropriate, relieve pain, and provide basic life support [2, 17].

According to the available data, approximately 2% of all patients with MI undergo urgent coronary artery bypass grafting (CABG) during hospitalization due to ACS [4]. Identification of patients requiring CABG is based on the results of imaging of the coronary arteries (coronary angiography) and therefore is not possible in the pre-hospital period. However, the fact that some patients may require urgent cardiac surgery shortly after establishing the diagnosis of ACS by the medical emergency team should somehow affect and define the pre-hospital management strategy in these cases. Whenever possible, direct transport of the highest risk patients (STEMI and NSTE-ACS of very high risk) to centres with both invasive cardiology and cardiac surgery facilities should be considered. It should be stressed however, that preference for this category of hospitals must not cause delay of invasive diagnostics [1].

To ensure high quality of care in ACS patients, a working diagnosis, pivotal statements, decisions, medications, and time-points should be registered and monitored. If projected target times are not met, then local interventions are needed to improve performance of the system [2].

**Chest pain treatment**

Morphine is the most commonly used analgesic in patients with ACS at the pre-hospital stage, particularly in those with MI, due to its potential positive effect on the pathophysiology of ACS, high efficacy in symptomatic management of chest pain, wide availability, and long-term experience of clinical use [1, 2, 18]. However, the use of morphine quite commonly produces adverse effects, such as bradycardia, arterial hypotension, and impairment of the intestinal propulsive function, and also sometimes a suppression of respiratory function [1, 19]. Moreover, morphine use is associated with slower uptake, delayed onset of action, and diminished effects of oral antiplatelet agents (i.e. clopidogrel, ticagrelor, and prasugrel) [2, 20–23]. There are no randomized clinical studies evaluating the safety of morphine in patients with ACS, and the data from registries are equivocal [24–26]. Moreover, results of numerous clinical trials indicate a possible negative effect of morphine on the extent of MI and mortality rate [25, 27]. As there is no effective alternative to morphine in chest pain management in patients with ACS, this medicine reappeared in the latest ESC guidelines concerning the management of STEMI, but with diminished class of recommendations (IIa) when compared with the previous edition (I) [2, 28]. The most recent guidelines concerning the management of NSTE-ACS provide no official recommendation for the use of morphine in this group of patients. However, the authors of these guidelines have stated that the administration of opioids is reasonable in NSTE-ACS patients with sustained severe chest pain who are waiting for urgent coronary angiography [10]. It should be noted that all these recommendations are solely based on the expert opinions (level of evidence — C) (Fig. 1).

Considering the available knowledge, routine withdrawal from morphine use in ACS patients should not be recommended. It seems reasonable to reserve morphine administration only for those patients who report severe chest pain or present with signs of acute heart failure (e.g. resting dyspnoea). Moreover, use of the minimal effective dose with a view to limit the adverse effects of morphine should be applied [1]. Also, when morphine is used, the administration of oral antiplatelet drugs in a crushed form may be

<table>
<thead>
<tr>
<th>Previous guidelines</th>
<th>Class of recommendation</th>
<th>Level of evidence</th>
<th>Current guidelines</th>
<th>Class of recommendation</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI 2012</td>
<td>I</td>
<td>C</td>
<td>2017</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>NSTE-ACS 2011</td>
<td>*</td>
<td>*</td>
<td>2015</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

**Figure 1.** European Society of Cardiology recommendations for use of morphine in patients with acute coronary syndromes; NSTE-ACS — non-ST-segment elevation acute coronary syndrome; STEMI — ST-segment elevation myocardial infarction; *No official recommendation.
considered. It was demonstrated that crushing the tablets accelerates their absorption from the gastrointestinal tract and shortens the time to onset of action [29–32]. Moreover, recently performed research revealed that concomitant intravenous injection of metoclopramide improves ticagrelor absorption despite the use of morphine (NCT02939235). Thus, concomitant intravenous injection of metoclopramide should be considered in patients with ACS treated with morphine. Additionally, a mild tranquillizer (e.g. benzodiazepine) should be considered in very anxious patients [2]. Due to potential harmful effect of oxygen in uncomplicated MI patients it should be used only in hypoxic patients with arterial oxygen saturation (SaO₂) < 90% [2, 33].

Antiplatelet treatment in ACS patients

Activation and aggregation of platelets play a key role in the pathophysiology of ACS, including MI [34, 35]. Restriction of excessive platelet activation and inhibition of platelet aggregation with DAPT, including acetylsalicylic acid (ASA) and one of the P2Y12 receptor inhibitors, is a standard of care in patients with ACS [2, 3, 10, 36].

ASA therapy in patients with ACS

Acetylsalicylic acid is an irreversible inhibitor of platelet cyclooxygenase isoenzyme type 1 (COX-1). According to the current guidelines, administration of an oral, rapidly absorbed ASA formulation in a loading dose of 150–300 mg is recommended in all ACS patients with no contraindications and no history of prior chronic use of ASA. When oral intake is not possible, ASA can be administered intravenously in the dose of 75–150 mg, however the i.v. formulation of ASA is not available in Poland. In STEMI and very high risk NSTE-ACS patients treatment should be applied as early as possible, i.e. upon the first medical contact. Then, all patients should receive chronic therapy with ASA 75–100 mg q.d. [2, 3, 10].

Table 1. Comparison of P2Y12 receptor inhibitors recommended by the European Society of Cardiology.

<table>
<thead>
<tr>
<th></th>
<th>Clopidogrel</th>
<th>Prasugrel</th>
<th>Ticagrelor</th>
<th>Cangrelor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical class</td>
<td>Thienopyridine</td>
<td>Thienopyridine</td>
<td>Cyclopentyl-triazolo-pyrimidine</td>
<td>Adenosine triphosphate analogue</td>
</tr>
<tr>
<td>Administration route</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Standard dosing:</td>
<td>Loading dose 300 or 600 mg</td>
<td>Maintenance dose 1 × 75 mg or 1 × 150 mg</td>
<td>1 × 10 mg or 1 × 5 mg</td>
<td>180 mg</td>
</tr>
<tr>
<td>Prodrug</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>P2Y12 receptor binding</td>
<td>Irreversible</td>
<td>Irreversible</td>
<td>Reversible</td>
<td>Reversible</td>
</tr>
<tr>
<td>Onset of antiplatelet effect</td>
<td>2–6 h#</td>
<td>30 min#</td>
<td>30 min#</td>
<td>2 min</td>
</tr>
<tr>
<td>Offset of antiplatelet effect</td>
<td>3–10 days</td>
<td>5–10 days</td>
<td>3–4 days</td>
<td>1–2 h</td>
</tr>
<tr>
<td>Recommended withdrawal before surgery</td>
<td>5 days</td>
<td>7 days</td>
<td>5 days</td>
<td>1 hour</td>
</tr>
</tbody>
</table>

#Data from healthy volunteers and patients with stable coronary disease. In patients with acute coronary syndromes the onset of action is probably delayed.

Platelet P2Y12 receptor inhibitors

The current recommendations concerning the treatment of patients with ACS emphasize the need to use DAPT for 12 months following ACS, unless contraindicated due to an excessive risk of bleeding — class of recommendation I, level of evidence A. This recommendation is valid for patients both with STEMI and NSTE-ACS [2, 10, 36, 37].

Currently, oral platelet P2Y12 inhibitors available in Poland are: clopidogrel, prasugrel, and ticagrelor. A registered, but still unavailable medication of this group is cangrelor — a compound designed for intravenous use only. Clopidogrel and prasugrel are pro-drugs and require activation in the liver into active metabolites irreversibly blocking the P2Y12 receptor, whereas ticagrelor and cangrelor are active drugs, which directly and reversibly block this receptor (Table 1) [36]. The guidelines preferentially recommend the newer P2Y12 inhibitors (prasugrel and ticagrelor) due to their faster,
more potent, and more uniform anti-aggregation effect translating into better clinical outcomes as compared with clopidogrel [1, 2, 10, 38–42].

When starting the treatment with P2Y12 inhibitors one should always be aware of contraindications for these drugs. Prasugrel is contraindicated in patients with a history of intracranial hemorrhage, ischemic cerebral stroke or transient ischemic attacks, or with active bleeding. Prasugrel is generally not recommended for patients above 75 years of age or with body weight below 60 kg. Also, ticagrelor is contraindicated in patients with a history of intracranial hemorrhage or with an active bleeding. Moreover, both prasugrel and ticagrelor are not recommended for use in dialysis patients or in those requiring chronic oral anticoagulation. When neither of these agents is available or if they are contraindicated, clopidogrel should be administered instead [43].

Many patients presenting with ACS require long-term oral anticoagulation. The concomitant use of DAPT and oral anticoagulation increases the risk of bleeding complications 2- to 3-fold when compared to anticoagulation alone [44–47]. Clopidogrel is the only P2Y12 inhibitor to be used in combination with oral anticoagulants (acenocoumarol, apixaban, dabigatran, rivaroxaban, or warfarin) [2]. Use of ticagrelor or prasugrel as a part of triple therapy is not recommended — class of recommendation III, level of evidence C [2, 3, 10].

Based on theoretical evidence derived from pharmacokinetic and pharmacodynamic properties as well as on the results of clinical studies, cangrelor appears to be the optimal P2Y12 inhibitor for ACS patients requiring urgent invasive treatment [48, 49]. Due to its rapid onset of action this compound may be considered in patients not pretreated with oral P2Y12 receptor inhibitors at the time of PCI or in those who are considered unable to absorb oral agents, particularly in unconscious patients, patients with post-cardiac arrest syndrome, or patients treated with mild therapeutic hypothermia, when gastrointestinal absorption of medications is impaired [2, 50, 51]. Unfortunately, cangrelor is not currently available in Poland.

Platelet P2Y12 receptor inhibitors in the treatment of patients with STEMI

ST-segment elevation MI is most commonly caused by total occlusion of a coronary artery, which results in progressive necrosis of myocardial cells. This implies the necessity to restore patency of the occluded artery as soon as possible. The preferred method of coronary revascularization is PCI [2, 36]. In STEMI patients potent P2Y12 inhibitor (prasugrel or ticagrelor), or clopidogrel if these are not available or are contraindicated, is recommended before or at latest at the time of PCI, and should be maintained for 12 months, unless contraindications such as excessive risk of bleeding exist — class of recommendation I, level of evidence A [2, 52, 53]. The available data suggest that, as prompt as possible, administration of P2Y12 receptor inhibitor may be preferable to achieve early efficacy [2]. Thus, a P2Y12 receptor inhibitor should be administered at the first contact with the healthcare system [36]. Although this approach appears to be justified, currently there are no randomized clinical trials demonstrating clear clinical benefits of this treatment strategy [1]. Administration of oral P2Y12 inhibitors in pre-hospital management of patients with STEMI is considered to be safe [54]. In patients with STEMI prasugrel (loading dose of 60 mg) and ticagrelor (loading dose of 180 mg) are both equally recommended [1–3, 36]. As mentioned earlier, when prasugrel or ticagrelor are unavailable or contraindicated, a loading dose of clopidogrel (600 mg) should be administered [2, 36]. In patients who have already received a loading dose of clopidogrel the antiplatelet therapy should be switched to ticagrelor at a loading dose of 180 mg (class of recommendation I, level of evidence B), which is not recommended for prasugrel [53].

Prasugrel is also not indicated in patients with ACS in whom coronary anatomy is not known and an indication for PCI is not clearly established, with the exception of STEMI patients scheduled to undergo immediate coronary catheterization and PCI, if clinically indicated [3].

Platelet P2Y12 receptor inhibitors in the treatment of patients with NSTE-ACS

While early initiation of antiplatelet therapy and urgent coronary reperfusion are recommended for patients with STEMI, in patients with NSTE-ACS the indications and recommended timeframes for diagnostics and potential invasive treatment depend primarily on the risk stratification [1]. The immediate interventional approach (within 2 h) is indicated in very high risk NSTE-ACS patients. Similar to STEMI, DAPT, including ASA and one of the P2Y12 inhibitors, is also recommended in patients with NSTE-ACS, unless contraindicated, e.g. due to excessive bleeding risk [10]. The guidelines concerning the treatment of NSTE-ACS contain information that therapy with P2Y12 inhibitors should be instituted immediately after establish-
ing the diagnosis of NSTE-ACS, regardless of the management strategy. In this group of patients the preferred P2Y12 inhibitors are prasugrel and ticagrelor, with equal recommendations — class of recommendation I, level of evidence B [10]. However, in patients with NSTE-ACS prasugrel should not be given prior to coronary angiography or when qualified for conservative treatment — class of recommendation III, level of evidence B [10]. These limitations preclude pre-hospital use of prasugrel in NSTE-ACS patients. In contrast, a ticagrelor loading dose of 180 mg followed by 90 mg b.i.d. is recommended in all patients with moderate-to-high risk of ischemic events, regardless of the initial management strategy, unless contraindicated. It is important to note that this recommendation also includes patients who had received clopidogrel previously, in this case clopidogrel should be discontinued at the time of initiation of ticagrelor treatment.

Conclusions

The ESC guidelines recommend the use of ticagrelor or prasugrel as preferred P2Y12 receptor inhibitors in all ACS patients, unless contraindicated, e.g. due to an excessive risk of bleeding [2, 3]. Contrary to prasugrel, ticagrelor is recommended for all patients with STEMI and moderate-to-high risk NSTE-ACS, regardless of the management strategy, including patients designated to conservative treatment and those pre-treated with clopidogrel. Use of clopidogrel in patients with STEMI or NSTE-ACS should be limited to situations when both ticagrelor and prasugrel are unavailable or contraindicated — class of recommendation I, level of evidence B [2, 3]. The choice of the optimal time to start the therapy with oral antiplatelet drugs is not well supported by results of the available clinical studies. Hence, it is difficult to formulate universal recommendations concerning early administration of DAPT. However, in very high-risk patients who require urgent invasive diagnostics and most commonly also PCI, it seems advisable to institute DAPT as soon as possible [55, 56]. A reasonable approach is to begin the treatment with a P2Y12 receptor inhibitor based on the administration timing tested for the drug in the approval studies (i.e. as soon as possible and deemed safe for clopidogrel and ticagrelor, or after the indication for PCI is established based on coronary anatomy for prasugrel in NSTE-ACS) [3, 57–59]. In ACS patients treated with CABG, therapy with ticagrelor is preferred due to favourable results in reduction of risk of adverse cardiovascular events, including death rates, as compared with clopidogrel, without increasing the risk of severe CABG-related bleeding [55]. Therefore, when initiating antiplatelet therapy in the pre-hospital setting, it seems justified to prefer ticagrelor as the drug of first choice in patients who may potentially require urgent cardiac surgery [1].

It should also be noted that, in accordance with the Directive of the Minister of Health dated 20 April 2016, paramedics and emergency medical team members are allowed to (after ECG tele-transmission and consultation with the physician evaluating the ECG) administer some P2Y12 inhibitors, namely clopidogrel and ticagrelor, but not prasugrel. In the periprocedural period ACS patients require antithrombotic treatment apart from DAPT, and according to the above-mentioned Directive of the Minister of Health, unfractionated heparin (70–100 U/kg) is the only antithrombotic agent that can be administered by paramedics and emergency medical team members [56].

In the pre-hospital period patients with ACS may experience vomiting with risk of loss of yet unabsorbed antiplatelet drugs. In such cases the time elapsed from drug intake to vomiting and the potential presence of tablets in the vomited content should be documented. The decision on administration of an additional dose of antiplatelet drugs should be left to the discretion of the physician at the destination hospital.

Importantly, despite several novelties included in the 2017 ESC guidelines for the management of STEMI and 2017 focused update on DAPT, general recommendations for the pre-hospital management of patients with ACS remain unaltered, especially concerning suggested antiplatelet therapy.

Summary

1. Use of ECG tele-transmission and teleconsultation systems should be a part of standard management in all patients with suspected ACS.
2. In order to make the therapeutic management of STEMI patients uniform, after preliminary diagnosis and teleconsultation with a cardiologist, if no contraindications exist, DAPT should be initiated (ASA 300 mg; ticagrelor 180 mg) (Fig. 2).
3. Routine pre-hospital initiation of DAPT (ASA 300 mg; ticagrelor 180 mg) is advisable in very high risk NSTE-ACS patients, in whom the preliminary assessment indicates the need for urgent invasive treatment.
4. Considering the lack of consistent data, analgesic treatment applied in patients with ACS during their transfer to hospital should be chosen and adjusted on an individual basis. Use of non- opioid drugs is not recommended in such conditions due to increased risk of bleeding when used simultaneously with DAPT. Due to interactions with oral antiplatelet drugs, care must be taken when morphine or perhaps when other opioids are used.


Figure 2. Algorithm for pre-hospital management of patients with acute coronary syndromes (modified and adopted from [1]); DAPT — dual antiplatelet therapy (preferred treatment: acetylsalicylic acid + ticagrelor); ECG — electrocardiography; NSTE-ACS — non-ST-segment elevation acute coronary syndrome; STEMI — ST-segment elevation myocardial infarction; *If required.
Opolski: none; Dariusz Dudek: fee for lectures and involvement in AstraZeneca advisory board; Jacek Legutko: fee for lectures and involvement in AstraZeneca advisory board; Marzena Zielińska: fee for lectures for AstraZeneca; Jarosław Wójcik: none.

References


Jacek Kubica et al., Treatment of patients with ACS: Recommendations for emergency teams


